CD40 and pancreatic adenocarcinoma: Recently, CD40 was discovered as an emerging target in cancer immunotherapy, and CD40 agonistic therapies are being evaluated in antitumor trials for different cancer types including non-Hodgkin's lymphoma, advanced urothelial carcinoma, malignant melanoma, pancreatic adenocarcinoma, renal cells carcinoma, NSCLC, and glioma (12).